muzastotug
muzastotug: 6 clinical trials tracked.
muzastotug evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about muzastotug, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 3 study sponsors
Related indications
Clinical Trial Registry Records (6)
A Phase I Clinical Trial of Ivonescimab and ADG126, Alone, and in Combination With 5-FU/LV or FOLFIRI in MSS Advanced/Metastatic Colorectal Cancer
Primary endpoint: Incidence of dose limiting toxicities
Phase II Trial of Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Primary endpoint: Rate of Major Pathologic Response (MPR)
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Primary endpoint: Dose Limiting Toxicities (DLTs)
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors
Primary endpoint: Dose escalation part 1A, 1C and Japan Cohort F: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors
Primary endpoint: Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Primary endpoint: Objective Response Rate (ORR)